Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ETCompany ParticipantsTim Power - Head of IRChris Viehbacher ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Ionis relies on upfront payments and licensing fees from partners, as well as Spinraza royalties, to drive revenue today, but its rapidly advancing portfolio should help diversify revenue. 2025 is ...

The quick uptake has come despite the established presence on the market of Biogen’s Spinraza (nusinersen), an antisense drug given by injection ... efficacy data with intrathecal delivery ...

Specific points covered included that nusinersen may modify disease severity and necessitate ongoing medical intervention (intrathecal injections); that patients do not uniformly have a promising ...

“We are pleased to announce that our applications for the higher dose regimen of nusinersen are now under review in ... the first disease-modifying therapy approved for SMA, is given via intrathecal ...

The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg doses 14 days apart, and higher maintenance regimen, 28 mg, every 4 months, compared to the approved ...

Weight loss injections are prescription medications to help with weight loss. They can help alter a person’s appetite and metabolism, curbing hunger and reducing calorie intake. Weight loss ...

Good morning. My name is Jennifer, and I will be your conference operator today. At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business ...